Ampio Pharma (AMPE) CEO Issues Letter to Shareholders
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/10/2026
- Wall St slightly higher as SK Hynix's stellar debut limits losses in chip stocks
- Oil prices fall on hopes for smoother shipping in Strait of Hormuz
- The real reason Meta shares are surging has nothing to do with its new AI model
- Stifel lifts Shopify to Buy, sees agentic commerce as next growth catalyst
- Delta Air Lines stock climbs on earnings beat and strong guidance
- Key things to know ahead of SK Hynix’s blockbuster US listing
- Almonty Industries (ALM) PT Raised to $33 at DA Davidson
- Meta falls as massive AI infrastructure spending plans overshadow chip progress
- S&P Downgrades Oracle To 'bbb-/A-3'; Outlook Stable
- The real reason Meta shares are surging has nothing to do with its new AI model
Ampio Pharmaceuticals Issues Letter to Stockholders
August 3, 2022 8:30 AM EDTENGLEWOOD, Colo., Aug. 3, 2022 /PRNewswire/ --Â Ampio Pharmaceuticals, Inc. (NYSE American: AMPE), today released the following letter to stockholders from its Chairman, Kevin Buchi and Chief Executive Officer, Mike Martino.
